MYELO-CAN:TXA
Phase 2 Recruiting
75 enrolled
ASC4TARGET
Phase 2 Recruiting
20 enrolled
MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
Phase 2 Recruiting
2,000 enrolled
At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer
Phase 2 Recruiting
220 enrolled
Testing the Effects of Novel Therapeutics for Newly Diagnosed, Untreated Patients With High-Risk Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Phase 2 Recruiting
335 enrolled
Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase
Phase 2 Recruiting
50 enrolled
MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases
Phase 2 Recruiting
132 enrolled
Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome
Phase 2 Recruiting
80 enrolled
Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm
Phase 2 Recruiting
40 enrolled
A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia
Phase 2 Recruiting
76 enrolled
A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)
Phase 2 Recruiting
62 enrolled
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
Phase 2 Recruiting
30 enrolled
ALERTCML
Phase 2 Recruiting
100 enrolled
Study of Canakinumab in Patients With Myelofibrosis
Phase 2 Recruiting
14 enrolled
MORE
Phase 2 Recruiting
37 enrolled
ACCELERATE
Phase 2 Recruiting
358 enrolled
Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms
Phase 2 Recruiting
25 enrolled
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Phase 2 Recruiting
31 enrolled
Graft Versus Host Disease-Reduction Strategies for Donor Blood Stem Cell Transplant Patients With Acute Leukemia or Myelodysplastic Syndrome (MDS)
Phase 2 Recruiting
120 enrolled
A Study to Assess the Effectiveness and Safety of Pacritinib in Patients With VEXAS Syndrome (PAXIS)
Phase 2 Recruiting
78 enrolled
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
Phase 2 Recruiting
216 enrolled
Ponatinib Hydrochloride as Second Line Therapy in Treating Patients With Chronic Myeloid Leukemia in Chronic Phase Resistant or Intolerant to Imatinib Mesylate, Dasatinib, or Nilotinib
Phase 2 Recruiting
50 enrolled
Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene Mutation
Phase 2 Recruiting
50 enrolled
Phase II Study Assessing Efficacy and Safety of Asciminib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.
Phase 2 Recruiting
50 enrolled
A Phase 2 Study Evaluating Olutasidenib in Patients With IDH1-mutated Clonal Cytopenia of Undetermined Significance and Lower-risk Myelodysplastic/Syndromes/Chronic Myelomonocytic Leukemia.
Phase 2 Recruiting
15 enrolled
A Phase 2, Open-Label Study of DISC-3405 in Participants With Polycythemia Vera (PV)
Phase 2 Recruiting
60 enrolled
Pacritinib With Standard of Care Azacitidine or Decitabine as a Bridge to Allogeneic Hematopoietic Stem Cell Transplant for Patients With Accelerated and Blast Phase Myeloproliferative Neoplasms
Phase 2 Recruiting
27 enrolled
Phase IIa Study on Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera
Phase 2 Recruiting
60 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies
Phase 2 Recruiting
60 enrolled
Co-Transplant of an Unmodified Haplo-Identical Graft With Cord Blood
Phase 2 Recruiting
36 enrolled
Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes
Phase 2 Recruiting
50 enrolled
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Phase 2 Recruiting
160 enrolled
Combination Chemotherapy (FLAG-Ida) Followed Immediately by Reduced-Intensity Total Body Radiation Therapy and Donor Hematopoietic Cell Transplant for the Treatment of Adults Age 60 and Older With Newly Diagnosed Adverse-Risk Acute Myeloid Leukemia or Other High-Grade Myeloid Cancer
Phase 2 Recruiting
20 enrolled
Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Phase 2 Recruiting
54 enrolled
Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia
Phase 2 Recruiting
102 enrolled
Ruxolitinib in Thrombocythemia and Polycythemia Vera
Phase 2 Recruiting
60 enrolled
Reparixin in Patients With Myelofibrosis Myeloproliferative Neoplasms Research Consortium (MPN-RC 120)
Phase 2 Recruiting
26 enrolled
Metabolically Optimized, Non-cytotoxic Low Dose Weekly Decitabine/Venetoclax in MDS and AML
Phase 2 Recruiting
91 enrolled 26 charts
The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment Satisfaction in Cancer Patients Living in the Florida Panhandle and Surrounding Areas
Phase 2 Recruiting
27 enrolled
TOKIN
Phase 2 Recruiting
100 enrolled
Study of Venetoclax and Azacitidine in Advanced BCR-ABL Negative Myeloproliferative Neoplasms
Phase 2 Recruiting
40 enrolled
TREATMORE
Phase 2 Recruiting
54 enrolled
Luspatercept for Anemia in Lower Risk MDS or Non-proliferative MDS/MPN Neoplasms
Phase 2 Recruiting
70 enrolled
IAMFIT
Phase 2 Recruiting
80 enrolled
CPX-351 and Ivosidenib for the Treatment of IDH1 Mutated Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
Phase 2 Recruiting
30 enrolled
Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers
Phase 2 Recruiting
100 enrolled
APTBCy
Phase 2 Recruiting
60 enrolled
RAFA
Phase 2 Recruiting
70 enrolled
Cladribine, Idarubicin, Cytarabine, and Venetoclax in Treating Patients With Acute Myeloid Leukemia, High-Risk Myelodysplastic Syndrome, or Blastic Phase Chronic Myeloid Leukemia
Phase 2 Recruiting
508 enrolled
Personalized NK Cell Therapy in CBT
Phase 2 Recruiting
100 enrolled